5-Amino-1MQ (5mg & 10mg)

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound studied for its effects on nicotinamide N-methyltransferase pathways, synthesized and lyophilized in the USA. Each batch is purified by HPLC and identity-confirmed by mass spectrometry, with purity exceeding 99% and independent third-party testing certificates available per lot. Supplied for laboratory research use only.

Researchers using 5-Amino-1MQ (5mg & 10mg) often combine dose-response assays with stability testing to establish reproducible experimental baselines.

Interest in 5-Amino-1MQ (5mg & 10mg) has grown alongside comparative work on incretin-related pathways and substrate utilization in cultured systems.

5-Amino-1MQ (5mg & 10mg) serves as a research tool for examining the interplay between peptide signaling and metabolic endpoints in experimental designs.

This product is available in 5mg and 10mg. Each vial contains lyophilized peptide at the labeled quantity; wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with 5-Amino-1MQ (5mg & 10mg). Summaries are provided for orientation only and reflect the cited sources.

Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity^[1] — This landmark study investigated the role of nicotinamide N-methyltransferase (NNMT) in adipose tissue and demonstrated that NNMT expression is elevated in obesity. Knockdown of NNMT was reported to increase energy expenditure and protect against diet-induced obesity in mice. The findings established NNMT as a target for obesity therapy and provided the mechanistic basis for NNMT inhibitors such as 5-Amino-1MQ. (Nature 2014)

Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice^[2] — This study examined the effects of combined NNMT inhibition and a reduced-calorie diet in diet-induced obese mice. The authors reported that the combination normalized body composition, reduced liver adiposity, and enhanced metabolic benefits relative to diet alone. The results support NNMT inhibition as an adjunct to dietary intervention for weight management. (Scientific Reports 2021)

Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice^[3] — This study explored the gut microbiome changes that accompany reduced-calorie diet combined with NNMT inhibition in diet-induced obese mice. The authors reported that the intervention produced a distinct cecal microbiome profile associated with improved metabolic regulation. The findings suggest gut microbial remodeling as a potential pathway contributing to the metabolic effects of NNMT inhibition. (Scientific Reports 2022)

Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction^[4] — This study investigated the effects of oral NNMT inhibition with 5-Amino-1MQ in diet-induced obese mice. The authors reported dose-dependent limitation of weight and fat gain, improved glucose tolerance, and attenuation of hepatic steatosis. The results indicate that 5-Amino-1MQ may mitigate obesity-related metabolic dysfunction. (Diabetes, Obesity and Metabolism 2023)

References

1. Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang Y, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature. 2014. pmc.ncbi.nlm.nih.gov/articles/PMC4107212/
2. Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. "Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice." Scientific Reports. 2021. link.springer.com/article/10.1038/s41598-021-85051-6
3. Dimet-Wiley A, Wu Q, Wiley JT, Eswar A, Neelakantan H, Savidge T, Watowich S. "Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice." Scientific Reports. 2022. pubmed.ncbi.nlm.nih.gov/35013352/
4. Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. "Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction." Diabetes, Obesity and Metabolism. 2023. www.semanticscholar.org/paper/Nicotinamide-N-methyltransferase-inhibi…

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.